Cargando…
Vaccination therapy for inflammatory bowel disease
Recently, several novel medications, such as Ustekinumab, Infliximab, and Vedolizumab, have emerged as potential options for inflammatory bowel disease(IBD) management. Despite achieving some effects in clinical applications, these therapies are still plagued by inadequate response rates and adverse...
Autores principales: | Liu, Yafei, Liao, Fei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543345/ https://www.ncbi.nlm.nih.gov/pubmed/37771317 http://dx.doi.org/10.1080/21645515.2023.2259418 |
Ejemplares similares
-
Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023
por: Sun, Ming-Yao, et al.
Publicado: (2023) -
Progress in Guillain–Barré syndrome immunotherapy—A narrative review of new strategies in recent years
por: Yao, Jiajia, et al.
Publicado: (2023) -
The relationship between sublingual immunotherapy for allergic rhinitis and the risk of symptoms in patients with COVID-19 infection
por: Zhang, Shipeng, et al.
Publicado: (2023) -
Epitope-based precision immunotherapy of Type 1 diabetes
por: Firdessa Fite, Rebuma, et al.
Publicado: (2023) -
The complicated use of dupilumab in the treatment of atypical generalized pemphigus erythematosus: A report of two cases
por: Chen, Jie, et al.
Publicado: (2023)